SCHEMBL20792882

SCHEMBL20792882

CC(C)(C)OC(=O)N1CCc2c(cnn2C2CCOCC2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 2/20 0.48
▸ ESR2 Q92731 1/20 0.44
▸ MAPT P10636 2/20 0.44
▸ RECQL P46063 1/20 0.44
▸ NR1H2 P55055 2/20 0.43
▸ MTOR P42345 6/20 0.43
▸ PIK3CA P42336 5/20 0.43
▸ PIK3CG P48736 5/20 0.43
▸ ATR Q13535 2/20 0.43
▸ AURKB Q96GD4 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ GPR119 Q8TDV5 1/20 0.39
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ PIK3CD O00329 1/20 0.39
▸ PIK3R2 O00459 1/20 0.39
▸ PIK3CB P42338 1/20 0.39
▸ PIK3R5 Q8WYR1 1/20 0.39
▸ PIK3R3 Q92569 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16217193 0.92 HPGDS (0.52) HPGDSESR2MAPTNR1H2GPR119
SCHEMBL23852254 0.90 HPGDS (0.50) HPGDSESR2MAPTNR1H2GPR119
SCHEMBL23794840 0.85 HPGDS (0.48) HPGDSESR2MAPTNR1H2DDB1
SCHEMBL31739445 0.85 HPGDS (0.46) HPGDSESR2MAPTNR1H2GPR119
SCHEMBL23852997 0.85 HPGDS (0.48) HPGDSESR2MAPTNR1H2DDB1
SCHEMBL31739486 0.84 HPGDS (0.45) HPGDSESR2MAPTNR1H2GPR119
SCHEMBL16210651 0.83 ESR2 (0.48) HPGDSESR2MAPTNR1H2GPR119
SCHEMBL23851564 0.83 HPGDS (0.48) HPGDSESR2MAPTNR1H2DDB1
SCHEMBL30793215 0.83 HPGDS (0.42) HPGDSESR2MAPTNR1H2MTOR
SCHEMBL17846604 0.82 CREBBP (0.51) CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3672958-B1 ANNULATED GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2023-08-02 — — EP disclosed
US-20200289516-A1 ANNULATED GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2020-09-17 — — US disclosed
WO-2019037861-A1 ANNULATED GLYCOSIDASE INHIBITORS Asceneuron S.A. (CH) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289516-A1 ANNULATED GLYCOSIDASE INHIBITORS GAA, GBA3, ENGASE HPGDS 4517/4885ESR2 2527/4885MAPT 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback